CervoMed Inc. - 8-K Filing
CervoMed's Phase 2a trial results for neflamapimod in nfvPPA accepted as a late-breaking oral presentation at ISFTD Annual Meeting (Items: 7.01 of this Current Report on Form 8-K)
Tickers: $CRVO
CervoMed's Phase 2a trial results for neflamapimod in nfvPPA accepted as a late-breaking oral presentation at ISFTD Annual Meeting (Items: 7.01 of this Current Report on Form 8-K)
Tickers: $CRVO